To study the differences in adipose tissue, liver and circulating levels of RBP4 in lean versus obese, diabetic and obese insulin, non-diabetic subjects in relation to glucose fluxes and hepatic triglyceride content
ID
Source
Brief title
Condition
- Glucose metabolism disorders (incl diabetes mellitus)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Circulating and tissue levels of RBP4, in relation to: endogenous glucose
production; hepatic, peripheral and adipose tissue insulin sensitivity; hepatic
triglyceride content
Secondary outcome
Correlation levels of RBP4 with hepatic enzymes involved in gluconeogenesis
Background summary
Retinol binding protein (RBP4) is a small 21 kDa protein that belongs to the
family of lipocalins. RBP4 is primarily synthesized in hepatocytes, but other
sites of synthesis are known including adipocytes. Recently RBP4 has been
proposed as an adipokine that is involved in obesity-induced insulin
resistance. We aim to assess whether serum and tissue RBP4 levels are elevated
in these metabolically altered states and whether these levels are correlated
with glucose fluxes. This gives more insight in the pathophysiological role of
RBP4 in glucose intolerance and diabetes in obesity and will shed light on
whether it would be useful to develop agents that decrease RBP4 expression.
Study objective
To study the differences in adipose tissue, liver and circulating levels of
RBP4 in lean versus obese, diabetic and obese insulin, non-diabetic subjects in
relation to glucose fluxes and hepatic triglyceride content
Study design
Observational study
Study burden and risks
The hyperinsulinemic clamp and the use of stable isotopes are safe.
Hypoglycemia during the clamp will be avoided by measuring plasma glucose
regularly. The risk of bleeding from the liver and intra abdominal fat biopsies
will be reduced by checking local hemostasis during and twice after the biopsy.
If needed electrical coagulation will be performed. MRS does not pose a risk.
Meibergdreef 9
Amsterdam 1105 AZ
NL
Meibergdreef 9
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
Female; BMI > 35 kg/m2; Age between 26 and 50 years; Established T2DM
Exclusion criteria
Primary lipid disorder or secondary lipid disorder treated with fibrates; T2DM treated with thiazolidinediones, DPP4-inhibitors or GLP1-analogues; Any medical condition except for glucose intolerance, hypertension and secondary dyslipidemia; Bleeding disorder; Untreated primary hypothyroidism; Contra-indications for MR scanning
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL42240.018.12 |